Ten large-cap stocks were top performers last week, with First Majestic Silver leading gains at 25.23% following better-than-expected Q4 results. Other notable gainers include Moderna (19.68%) on FDA seasonal flu vaccine review news, Global Payments (19.52%) with strong Q4 earnings and a $2.6B buyback authorization, and Coinbase (11.32%). Companies like Omnicom, Garmin, Figma, and Pan American Silver also reported strong quarterly results and positive guidance.

BioNTech has filed a patent infringement lawsuit against Moderna, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE infringes on BioNTech's patented domain-based spike protein technology. BioNTech claims the technology targets specific domains of the spike protein rather than the full structure, enabling lower doses and improved storage stability. Moderna has not sought licensing rights or provided compensation, according to BioNTech. The lawsuit seeks monetary damages as Moderna's COVID-19 vaccine sales reached $1.168 billion through Q3 2025.

The global human vaccines market is projected to grow from USD 44.26 billion in 2025 to USD 62.45 billion by 2033, with a CAGR of 4.43%. Growth is driven by expanding immunization programs, technological advancements in mRNA and recombinant vaccines, and increased public health investments. mRNA vaccines and HPV vaccines are expected to grow fastest, while challenges include manufacturing complexity and regulatory compliance.

BioNTech announced the appointment of Kylie Jimenez as Chief People Officer effective March 1, 2026. Jimenez, a seasoned HR executive with over 20 years of experience at companies including Toyota, Johnson & Johnson, and Georg Fischer, will lead BioNTech's people strategy and organizational development as the company pursues its goal of becoming a multi-product oncology company by 2030.

BioNTech announced the appointment of Kylie Jimenez as Chief People Officer (CPO) effective March 1, 2026. Jimenez, who brings over 20 years of international HR experience from roles at Georg Fischer, Toyota, Johnson & Johnson, and General Mills, will lead BioNTech's personnel strategy and focus on talent acquisition, development, and fostering an inclusive corporate culture to support the company's goal of becoming a multi-product oncology company by 2030.

The global nanobiotechnology market is projected to grow from USD 172.81 billion in 2024 to USD 420.2 billion by 2034, driven by healthcare demand, R&D funding, and technological innovations in drug delivery and medical applications.

Pfizer forecasts lower 2026 earnings and sales, anticipating reduced COVID-19 product revenues and product patent losses, while maintaining focus on R&D and cost management strategies.

BioNTech and Bristol Myers Squibb reported promising interim data for pumitamig, a drug combination showing encouraging anti-tumor responses for triple-negative breast cancer patients with limited treatment options.

BioNTech and OncoC4 announced positive Phase-3 trial results for Gotistobart, a selective Treg modulator for lung cancer patients. The treatment showed a 54% reduction in death risk compared to standard chemotherapy, with a median overall survival not yet reached after 15 months of follow-up.

BioNTech and OncoC4 reported promising results for gotistobart, a selective Treg modulator, in treating squamous non-small cell lung cancer. The drug showed a 54% reduction in death risk compared to standard chemotherapy, with a median overall survival not yet reached at 15 months of follow-up.

BioNTech successfully met the minimum condition for its exchange offer to acquire CureVac, with 81.74% of CureVac shares tendered. The subsequent offering period will continue until December 18, 2025, allowing remaining shareholders to participate.

The article highlights Bristol Myers Squibb and Johnson & Johnson as attractive dividend stocks, despite facing challenges like patent cliffs and legal issues. Both companies demonstrate resilience through innovative product launches and consistent dividend growth.